Calmoseptine Dosing for Incontinence and Limited Mobility
Apply Calmoseptine topically to the affected perineal area up to 6 times daily or after each bowel movement in adults, following proper cleansing and drying of the skin. 1
Adult Dosing Protocol
Cleanse the affected area with mild soap and warm water, rinse thoroughly, then gently dry by patting or blotting with toilet tissue or soft cloth, or allow to air dry before application 1
Apply externally to the affected area up to 6 times daily or after each bowel movement 1
The product contains dimethicone as a skin protectant, which provides a moisture barrier to prevent incontinence-associated dermatitis (IAD) 1, 2
Pediatric Considerations
For children under 12 years of age, consult a physician before use 1
No specific pediatric dosing guidelines are established in the FDA labeling for Calmoseptine 1
Clinical Context and Rationale
The frequent application schedule (up to 6 times daily) is designed to maintain continuous barrier protection in patients with urinary incontinence, fecal incontinence, or both, who are at high risk for IAD 1, 2. The dimethicone component creates a protective barrier against moisture, friction, and irritants that contribute to skin breakdown 2, 3.
Key Application Principles
Timing matters: Apply after each episode of incontinence when practical, as this maintains the protective barrier and prevents prolonged exposure of skin to irritant bodily fluids 1, 2
Proper skin preparation is essential: The skin must be clean and dry before application to ensure optimal barrier function 1, 2
Gentle technique: Pat or blot dry rather than rubbing, as friction can denude fragile skin in elderly or compromised patients 2
Common Pitfalls to Avoid
Do not apply to wet or soiled skin, as this reduces barrier effectiveness and may trap moisture against the skin 1, 2
Avoid harsh alkaline soaps (pH > 7) during cleansing, as these disrupt the skin's natural acid mantle (pH 5.5) and increase susceptibility to bacterial colonization 2
Do not skip applications between incontinence episodes in high-risk patients, as gaps in barrier protection allow moisture and enzymatic activity from urine/feces to damage skin 2, 4